©2022 Stanford Medicine
An Open Label Treatment Use Protocol for Ibrutinib in Subjects With Relapsed or Refractory Mantle Cell Lymphoma
Trial ID: NCT01833039
The purpose of this study is to provide patients who have relapsed or refractory Mantle Cell Lymphoma (MCL) with early access to an investigational medication called ibrutinib (PCI-32765) and to collect safety information about the drug.
An Open-Label Treatment Use Protocol for Ibrutinib (PCI-32765) in Subjects With Relapsed or Refractory Mantle Cell Lymphoma
- Patients, 18 years of age and older, with Mantle Cell Lymphoma who have relapsed or
refractory disease after prior therapy are eligible.
- Patients eligible for enrollment in any other ongoing clinical study of ibrutinib are
- Patients previously treated with ibrutinib are not eligible.
- Patients enrolled in another interventional clinical study with therapeutic intent are
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Cancer Clinical Trials Office